Pennsylvania jury finds against Takeda in Actos lawsuit for $1.3 million in damages

SINGAPORE--It took a U.S. jury only two hours to decide to assess Takeda Pharmaceutical $1.3 million in punitive damages for the bladder cancer it ruled earlier were caused by Actos (pioglitazone) diabetes drug. The jury had already awarded $2.3 million in compensation to the Pennsylvania man, making Takeda now liable for $3.6 million in that case.

The company was expected to appeal, as it has in the four other suits it has lost because of Actos. It still faces about 4,500 other suits in the United States. Japan-based Takeda did not immediately respond to a request for comment.

When drug makers have been found liable in U.S. cases, the trend has been for juries to slap extremely heavy fines for punitive damages, almost always drastically reduced by higher courts.

In the Pennsylvania case brought by John Kristufek, the assessment was more in line with what appeals courts have deemed as more appropriate. Thus, if high courts agree with the Pennsylvania district court's decision regarding Takeda's guilt and that the $2.3 million in compensatory damages was justified, it also could decide the $1.3 in punitive damages was.

- read the Japan News story here

Related Stories:
Another Actos lawsuit reaches a jury for weary Takeda
Takeda back in court facing bladder cancer claims against Actos